Effect of Beta Blockers, Particularly Carvedilol, on Reducing the Risk of Events After Acute Myocardial Infarction

American Journal of Cardiology

Volumn 98, Issue 8, 2006, Pages 1115-1119

  Kopecky, Stephen L ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; AMIODARONE; ANTICOAGULANT AGENT; ANTIHYPERTENSIVE AGENT; ANTITHROMBOCYTIC AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; CARVEDILOL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FIBRINOLYTIC AGENT; METOPROLOL; METOPROLOL TARTRATE; PROPRANOLOL; TIMOLOL;

ACUTE HEART INFARCTION; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; CARDIOGENIC SHOCK; CARDIOVASCULAR RISK; DRUG EFFICACY; HEART LEFT VENTRICLE FAILURE; HEART REINFARCTION; HUMAN; HYPERTENSION; MORBIDITY; MORTALITY; NONHUMAN; PRIORITY JOURNAL; REVIEW;

ADRENERGIC ALPHA-ANTAGONISTS; ADRENERGIC BETA-ANTAGONISTS; CARBAZOLES; HUMANS; MYOCARDIAL INFARCTION; PROPANOLAMINES; TREATMENT OUTCOME;

EID: 33749263335     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2006.05.039     Document Type: Review

References (50)

1. American Heart Association. Heart Disease and Stroke Statistics-2005 Update. Dallas, Texas: American Heart Association, 2005.
2. Cleland J.G., Torabi A., and Khan N.K. Epidemiology and management of heart failure and left ventricular systolic dysfunction in the aftermath of a myocardial infarction. Heart 91 suppl (2005) ii7-ii13
3. Wu A.H., Parsons L., Every N.R., and Bates E.R. Hospital outcomes in patients presenting with congestive heart failure complicating acute myocardial infarction: a report from the Second National Registry of Myocardial Infarction (NRMI-2). J Am Coll Cardiol 40 (2002) 1389-1394
4. Hasdai D., Topol E.J., Kilaru R., Battler A., Harrington R.A., Vahanian A., Ohman E.M., Granger C.B., van de Werf F., Simoons M.L., et al. Frequency, patient characteristics, and outcomes of mild-to-moderate heart failure complicating ST-segment elevation acute myocardial infarction: lessons from 4 international fibrinolytic therapy trials. Am Heart J 145 (2003) 73-79
5. Antman E.M., Anbe D.T., Armstrong P.W., Bates E.R., Green L.A., Hand M., Hochman J.S., Krumholz H.M., Kushner F.G., Lamas G.A., et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction-executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1999 Guidelines for the Management of Patients With Acute Myocardial Infarction). Circulation 110 (2004) 588-636
6. Freemantle N., Cleland J., Young P., Mason J., and Harrison J. Beta-blockade after myocardial infarction: systematic review and meta-regression analysis. BMJ 318 (1999) 1730-1737
7. Borrello F., Beahan M., Klein L., and Gheorghiade M. Reappraisal of beta-blocker therapy in the acute and chronic post-myocardial infarction period. Am J Cardiol 93 (2004) 21-29
8. Reiter M.J., and Reiffel J.A. Importance of beta blockade in the therapy of serious ventricular arrhythmias. Am J Cardiol 82 suppl (1998) 9I-19I
9. Frishman W.H., and Chang C.M. Beta-adrenergic blockade in the prevention of myocardial infarction: a new theory. J Hypertens 9 suppl (1991) S31-S34
10. Hu Z.W., Shi X.Y., Lin R.Z., Chen J., and Hoffman B.B. Alpha1-adrenergic receptor stimulation of mitogenesis in human vascular smooth muscle cells: role of tyrosine protein kinases and calcium in activation of mitogen-activated protein kinase. J Pharmacol Exp Ther 290 (1999) 28-37
11. Packer M. Beta-adrenergic blockade in chronic heart failure: principles, progress, and practice. Prog Cardiovasc Dis 41 (1998) 39-52
12. Feuerstein G., Yue T.L., Ma X., and Ruffolo R.R. Novel mechanisms in the treatment of heart failure: inhibition of oxygen radicals and apoptosis by carvedilol. Prog Cardiovasc Dis 41 (1998) 17-24
13. Naccarelli G.V., and Lukas M.A. Carvedilol's antiarrhythmic properties: therapeutic implications in patients with left ventricular dysfunction. Clin Cardiol 28 (2005) 165-173
14. Feuerstein G.Z., Bril A., and Ruffolo Jr. R.R. Protective effects of carvedilol in the myocardium. Am J Cardiol 80 suppl (1997) 41L-45L
15. Bristow M.R. Mechanism of action of beta-blocking agents in heart failure. Am J Cardiol 80 suppl (1997) 26L-40L
16. Khandoudi N., Percevault-Albadine J., and Bril A. Comparative effects of carvedilol and metoprolol on cardiac ischemia-reperfusion injury. J Cardiovasc Pharmacol 32 (1998) 443-451
17. van der Does R., Hauf-Zachariou U., Pfarr E., Holtbrugge W., Konig S., Griffiths M., and Lahiri A. Comparison of safety and efficacy of carvedilol and metoprolol in stable angina pectoris. Am J Cardiol 83 (1999) 643-649
18. Yue T.L., Ma X.L., Wang X., Romanic A.M., Liu G.L., Louden C., Gu J.L., Kumar S., Poste G., Ruffolo R.R., and Feuerstein G.Z. Possible involvement of stress-activated protein kinase signaling pathway and Fas receptor expression in prevention of ischemia/reperfusion-induced cardiomyocyte apoptosis by carvedilol. Circ Res 82 (1998) 166-174
19. Olivetti G., Quaini F., Sala R., Lagrasta C., Corradi D., Bonacina E., Gambert S.R., Cigola E., and Anversa P. Acute myocardial infarction in humans is associated with activation of programmed myocyte cell death in the surviving portion of the heart. J Mol Cell Cardiol 28 (1996) 2005-2016
20. Dambrink J.H., Beukema W.P., van Gilst W.H., Peels K.H., Lie K.I., and Kingma J.H. Left ventricular dilatation and high-grade ventricular arrhythmias in the first year after myocardial infarction. CATS Investigators. Captopril and Thrombolysis Study. J Card Fail 1 (1994) 3-11
21. Jacob S., Rett K., and Henriksen E.J. Antihypertensive therapy and insulin sensitivity: do we have to redefine the role of beta-blocking agents?. Am J Hypertens 11 (1998) 1258-1265
22. Giugliano D., Acampora R., Marfella R., De Rosa N., Ziccardi P., Ragone R., De Angelis L., and D'Onofrio F. Metabolic and cardiovascular effects of carvedilol and atenolol in non-insulin-dependent diabetes mellitus and hypertension. A randomized, controlled trial. Ann Intern Med 126 (1997) 955-959
23. Jacob S., Rett K., Wicklmayr M., Agrawal B., Augustin H.J., and Dietze G.J. Differential effect of chronic treatment with two beta-blocking agents on insulin sensitivity: the carvedilol-metoprolol study. J Hypertens 14 (1996) 489-494
24. Bakris G.L., Fonseca V., Katholi R.E., McGill J.B., Messerli F.H., Phillips R.A., Raskin P., Wright Jr. J.T., Oakes R., Lukas M.A., et al., GEMINI Investigators. Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial. JAMA 292 (2004) 2227-2236
25. Cheng J., Niwa R., Kamiya K., Toyama J., and Kodama I. Carvedilol blocks the repolarizing K+ currents and the L-type Ca2+ current in rabbit ventricular myocytes. Eur J Pharmacol 376 (1999) 189-201
26. Karle C.A., Kreye V.A., Thomas D., Rockl K., Kathofer S., Zhang W., and Kiehn J. Antiarrhythmic drug carvedilol inhibits HERG potassium channels. Cardiovasc Res 49 (2001) 361-370
27. Amiodarone Trials Meta-Analysis Investigators. Effect of prophylactic amiodarone on mortality after acute myocardial infarction and in congestive heart failure: meta-analysis of individual data from 6500 patients in randomised trials. Lancet 350 (1997) 1417-1424
28. Nissen S.E., Tuzcu E.M., Schoenhagen P., Crowe T., Sasiela W.J., Tsai J., Orazem J., Magorien R.D., O'Shaughnessy C., and Ganz P. Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease. N Engl J Med 352 (2005) 29-38
29. Jenkins N.P., Keevil B.G., Hutchinson I.V., and Brooks N.H. Beta-blockers are associated with lower C-reactive protein concentrations in patients with coronary artery disease. Am J Med 112 (2002) 269-274
30. Yasunari K., Maeda K., Nakamura M., Watanabe T., Yoshikawa J., and Asada A. Effects of carvedilol on oxidative stress in polymorphonuclear and mononuclear cells in patients with essential hypertension. Am J Med 116 (2004) 460-465
31. CAPRICORN Investigators. Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. Lancet 357 (2001) 1385-1390
32. McMurray J., Kober L., Robertson M., Dargie H., Colucci W., Lopez-Sendon J., Remme W., Sharpe D.N., and Ford I. Antiarrhythmic effect of carvedilol after acute myocardial infarction: results of the Carvedilol Post-Infarct Survival Control in Left Ventricular Dysfunction (CAPRICORN) trial. J Am Coll Cardiol 45 (2005) 525-530
33. Australia/New Zealand Heart Failure Research Collaborative Group. Randomised, placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischaemic heart disease. Australia/New Zealand Heart Failure Research Collaborative Group. Lancet 349 (1997) 375-380
34. Packer M., Bristow M.R., Cohn J.N., Colucci W.S., Fowler M.B., Gilbert E.M., and Shusterman N.H. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. N Engl J Med 334 (1996) 1349-1355
35. Packer M., Coats A.J., Fowler M.B., Katus H.A., Krum H., Mohacsi P., Rouleau J.L., Tendera M., Castaigne A., Roecker E.B., et al. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 344 (2001) 1651-1658
36. Packer M., Fowler M.B., Roecker E.B., Coats A.J., Katus H.A., Krum H., Mohacsi P., Rouleau J.L., Tendera M., Staiger C., et al. Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) study. Circulation 106 (2002) 2194-2199
37. Hjalmarson A., Elmfeldt D., Herlitz J., Holmberg S., Malek I., Nyberg G., Ryden L., Swedberg K., Vedin A., Waagstein F., et al. Effect on mortality of metoprolol in acute myocardial infarction. A double-blind randomised trial. Lancet 2 (1981) 823-827
38. Hjalmarson A., Herlitz J., Holmberg S., Ryden L., Swedberg K., Vedin A., Waagstein F., Waldenstrom A., Waldenstrom J., Wedel H., et al. The Goteborg metoprolol trial. Effects on mortality and morbidity in acute myocardial infarction. Circulation 67 (1983) I26-I32
39. Herlitz J., Elmfeldt D., Holmberg S., Malek I., Nyberg G., Pennert K., Ryden L., Swedberg K., Vedin A., and Waagstein F. Goteborg Metoprolol Trial: mortality and causes of death. Am J Cardiol 53 suppl (1984) 9D-14D
40. Norwegian Multicenter Study Group. Timolol-induced reduction in mortality and reinfarction in patients surviving acute myocardial infarction. N Engl J Med 304 (1981) 801-807
41. Beta-Blocker Heart Attack Trial Research Group. A randomized trial of propranolol in patients with acute myocardial infarction. I. Mortality results. JAMA 247 (1982) 1707-1714
42. Beta-Blocker Heart Attack Trial Research Group. A randomized trial of propranolol in patients with acute myocardial infarction. II. Morbidity results. JAMA 250 (1983) 2814-2819
43. MIAMI Trial Research Group. Metoprolol in acute myocardial infarction. Mortality. The MIAMI Trial Research Group. Am J Cardiol 56 suppl (1985) 15G-22G
44. ISIS-1 Collaborative Group. Randomised trial of intravenous atenolol among 16 027 cases of suspected acute myocardial infarction: ISIS-1. First International Study of Infarct Survival Collaborative Group. Lancet 2 (1986) 57-66
45. Lopressor Intervention Trial Research Group. The Lopressor Intervention Trial: multicentre study of metoprolol in survivors of acute myocardial infarction. Lopressor Intervention Trial Research Group. Eur Heart J 8 (1987) 1056-1064
46. Roberts R., Rogers W.J., Mueller H.S., Lambrew C.T., Diver D.J., Smith H.C., Willerson J.T., Knatterud G.L., Forman S., and Passamani E. Immediate versus deferred beta-blockade following thrombolytic therapy in patients with acute myocardial infarction. Results of the Thrombolysis In Myocardial Infarction (TIMI) II-B Study. Circulation 83 (1991) 422-437
47. Gruberg L. COMMIT/CCS-2: Clopidogrel and Metoprolol in Myocardial Infarction Trial/Second Chinese Cardiac Study-The Metoprolol Arm. Medscape coverage of the American College of Cardiology 2005 Annual Scientific Session. Available at: http://www.medscape.com/viewarticle/501669?src=search . Accessed January 2005.
48. Chen Z.M., Pan H.C., Chen Y.P., Peto R., Collins R., Jiang L.X., Xie J.X., and Liu L.S. Early intravenous then oral metoprolol in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet 366 (2005) 1622-1632
49. Poole-Wilson P.A., Swedberg K., Cleland J.G., Di Lenarda A., Hanrath P., Komajda M., Lubsen J., Lutiger B., Metra M., Remme W.J., et al. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol or Metoprolol European Trial (COMET): randomised controlled trial. Lancet 362 (2003) 7-13
50. Torp-Pedersen C. The effect of metoprolol and carvedilol on cause-specific mortality in chronic heart failure patients. The Carvedilol or Metoprolol European Trial. Am Heart J 149 (2005) 370-376